Edition:
United States

Ablynx NV (ABLX.BR)

ABLX.BR on Brussels Stock Exchange

11.10EUR
11:35am EDT
Change (% chg)

€0.09 (+0.82%)
Prev Close
€11.01
Open
€11.22
Day's High
€11.25
Day's Low
€10.95
Volume
72,844
Avg. Vol
150,462
52-wk High
€14.69
52-wk Low
€8.21

ABLX.BR

Chart for ABLX.BR

About

Ablynx NV is a Belgium-based biopharmaceutical company engaged in the development of Nanobodies, proprietary therapeutic proteins based on single-domain antibody fragments, which combine the advantages of conventional antibody drugs with some of the features of small-molecule drugs. Ablynx NV has more than 30 proprietary and... (more)

Overall

Beta: 1.48
Market Cap(Mil.): €673.08
Shares Outstanding(Mil.): 61.13
Dividend: --
Yield (%): --

Financials

  ABLX.BR Industry Sector
P/E (TTM): 1,101.00 142.93 17.37
EPS (TTM): 0.01 -- --
ROI: -0.59 2.34 -5.89
ROE: -1.66 0.22 -5.30

BRIEF-Ablynx to receive 15 million euros milestone payment

* NOVEL NANOBODY TO START CLINICAL DEVELOPMENT IN OSTEOARTHRITIS - ABLYNX TO RECEIVE €15 MILLION MILESTONE PAYMENT

1:25am EDT

BRIEF-Ablynx Q1 revenues eur 9.1 million (2016 eur 27.4 million)

* Q1 OPERATING LOSS OF EUR 20.2 MILLION (2016: LOSS EUR 0.7 MILLION)

May 11 2017

BRIEF-Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of aTTP

* Ablynx completes patient recruitment in its Phase III HERCULES study of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP)

May 02 2017

BRIEF-Ablynx announces warrant exercise

* An additional 57,125 common shares have been issued by company in exchange for EUR 398,801.77 ($427,395.86) as result of exercise of warrants

Apr 21 2017

BRIEF-Ablynx FY revenue rises 10 pct

* FY net cash burn of EUR 72.2 million, in line with previously guided range of EUR 65-75 million

Feb 23 2017

BRIEF-Ablynx: Results support advancement of vobarilizumab into phase III development

* Ablynx to present additional data for its anti-IL-6R nanobody, vobarilizumab, a potential best-in-class treatment for rheumatoid arthritis

Feb 09 2017

BRIEF-Ablynx submits marketing authorisation for caplacizumab

* Ablynx submits a marketing authorisation application to the European medicines agency for caplacizumab, its anti-vwf nanobody, for the treatment of aTTP

Feb 06 2017

BRIEF-Ablynx's partner Merck reports encouraging results with nanobody

* Ablynx's partner, Merck KGaA, reports encouraging results with the bi-specific nanobody anti-il-17a/f (m1095) in a phase ib clinical study in patients with psoriasis

Jan 26 2017

BRIEF-Van Herk Investments announces 10.07 pct shareholding in Ablynx

* Van Herk Investments B.V. announces 10.07 pct shareholding in Ablynx, an increase from a former position of 5.40 pct (August 2016) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 24 2017

BRIEF-Ablynx has 61,076,074 shares outstanding after warrant exercise

* As a result of this transaction, Ablynx now has 61,076,074 shares outstanding Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Jan 18 2017

More From Around the Web

Earnings vs. Estimates